Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L
一项开放标签的 II 期临床试验纳入了 75 名晚期肝细胞癌患者,他们每日服用片剂形式的肝癌疫苗 hepcortespenlisimut-L。
期刊:Journal of Hepatocellular Carcinoma
影响因子:3.4
doi:10.2147/JHC.S122507
Tarakanovskaya, Marina G; Chinburen, Jigjidsuren; Batchuluun, Purev; Munkhzaya, Chogsom; Purevsuren, Genden; Dandii, Dorjiin; Hulan, Tsogkhuu; Oyungerel, Dandii; Kutsyna, Galyna A; Reid, Alan A; Borisova, Vika; Bain, Allen I; Jirathitikal, Vichai; Bourinbaiar, Aldar S